Download PDFPDF

Calprotectin instability may lead to undertreatment in children with IBD
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Response to Haisma S-M, et al. Arch Dis Child 2020;105:996–998.

    I read with great interest the article by Haisma et al. that reports on fecal calprotectin instability.(1) The authors are to be commended on their study. However, some points deserve comment.

    The authors tested the stability of calprotectin after the stool was homogenized. The clinical relevance of this is unclear since what is important is the stability of calprotectin in stool after collection and before analysis. The studies that have evaluated fecal calprotectin stability in this situation are in alignment; calprotectin is stable in unprocessed stool at room temperature for at least 3 days with some studies suggesting up to a week (for review see D’Amico et al.).(2)

    No support is provided for the statement by Haisma et al. that calprotectin instability in stool samples sent by mail may lead to errors in treat-to-target strategies. Indeed, the literature says otherwise.

    1. Haisma SM, van Rheenen PF, Wagenmakers L, Muller Kobold A. Calprotectin instability may lead to undertreatment in children with IBD. Arch Dis Child. 2020;105:996-8 doi: 10.1136/archdischild-2018-316584 [published Online First: 2019/01/19].
    2. D'Amico F, Rubin DT, Kotze PG, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021;9:451-60 doi: 10.1002/ueg2.12069 [published Online First: 2021/05/08].

    Conflict of Interest:
    None declared.